An assay to assess the microenvironment, immunogenic or immunosuppressive, of a tumor comprising the quantification in a bioptic sample of said tumor of: - the expression of the hMENA11a marker in tumor cells and in the stromal cells of said sample; - the expression of the FN1 marker in the stroma of said sample; - the expression of the CD3, CD8 and CD20 markers in the cells of said sample; and - the expression of the PDL1 marker in the tumor cells of said sample wherein, the expression of hMENA11a higher than a cutoff value of 50, identified by ROC analysis, in the tumor cells of said sample; the absence of expression of hMENA11a in the stromal cells of said sample; the expression of the FN1 marker lower than an intensity value, called score, equal to 2 in a staining intensity scale, from 0 to 3 in the stroma of said sample and the expression of the CD3, CD8 and CD20 markers in at least 5 cells per mm 2 in the tumor area or in the invasive margin of said sample; the presence of tertiary lymphoid structures consisting of an aggregate of B lymphocytes within the structure and T cells outside of the same, assessed respectively by the expression of CD20, CD8 and CD3 markers, are representative of an immunogenic tumor microenvironment, while the expression of hMENA1 1a lower than a cutoff value of 50 in the tumor cells of said sample; the expression of the FN1 marker equal to or greater than a cutoff value of score 2 in the stroma of said sample and the absence of expression of the CD3, CD8 and CD20 markers in cells within the tumor area or in the invasive margin of said sample are representative of an immunosuppressive tumor microenvironment; wherein: hMENA11a is the ENAH variant 1 ID: NM_001008493 splicing variant containing an additional exon; hMENADv6, hMENA splicing variant lacking exon 6 ID: EU255274.1; FN1 is fibronectin 1 Gene ID: 2335 PD-L1, is Programmed cell Death-ligand 1, alias CD274, Gene ID: 29126. - the expression of the hMENA11a marker in tumor cells and in the stromal cells of said sample; - the expression of the FN1 marker in the stroma of said sample; - the expression of the CD3, CD8 and CD20 markers in the cells of said sample; and - the expression of the PDL1 marker in the tumor cells of said sample the expression of hMENA11a higher than a cutoff value of 50, identified by ROC analysis, in the tumor cells of said sample; the absence of expression of hMENA11a in the stromal cells of said sample; the expression of the FN1 marker lower than an intensity value, called score, equal to 2 in a staining intensity scale, from 0 to 3 in the stroma of said sample and the expression of the CD3, CD8 and CD20 markers in at least 5 cells per mm 2 in the tumor area or in the invasive margin of said sample; the presence of tertiary lymphoid structures consisting of an aggregate of B lymphocytes within the structure and T cells outside of the same, assessed respectively by the expression of CD20, CD8 and CD3 markers, are representative of an immunogenic tumor microenvironment, while the expression of hMENA1 1a lower than a cutoff value of 50 in the tumor cells of said sample; the expression of the FN1 marker equal to or greater than a cutoff value of score 2 in the stroma of said sample and the absence of expression of the CD3, CD8 and CD20 markers in cells within the tumor area or in the invasive margin of said sample are representative of an immunosuppressive tumor microenvironment; wherein: hMENA11a is the ENAH variant 1 ID: NM_001008493 splicing variant containing an additional exon; hMENADv6, hMENA splicing variant lacking exon 6 ID: EU255274.1; FN1 is fibronectin 1 Gene ID: 2335 PD-L1, is Programmed cell Death-ligand 1, alias CD274, Gene ID: 29126. hMENA11a is the ENAH variant 1 ID: NM_001008493 splicing variant containing an additional exon; hMENADv6, hMENA splicing variant lacking exon 6 ID: EU255274.1; FN1 is fibronectin 1 Gene ID: 2335 PD-L1, is Programmed cell Death-ligand 1, alias CD274, Gene ID: 29126.